Imagine a world free from the grip of hepatitis C—a silent killer that affects millions—but recent insights reveal we're still grappling with significant obstacles on the path to eradication. New research, shared at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, offers concrete data on our progress toward the World Health Organization's (WHO) ambitious goals for eliminating hepatitis C virus (HCV), spotlighting stubborn shortfalls in reducing new infections and deaths globally. But here's where it gets controversial: Is the international community's commitment strong enough, or are we prioritizing the wrong strategies? Let's dive into the details and see what this means for our collective fight against this disease.
Hepatitis C, or HCV, is a viral infection that primarily attacks the liver, often leading to chronic issues like cirrhosis or liver cancer if untreated. It's transmitted through blood, such as via shared needles or contaminated medical equipment. The WHO labeled it a major global health challenge back in 2015 and outlined targets for 2030: slashing new infections to fewer than 5 per 100,000 people and mortality to under 2 per 100,000. To guide this effort, they introduced the Path to Elimination (PTE) framework, which categorizes progress into bronze, silver, and gold levels based on achievements in prevention, diagnosis, and treatment. Think of it like tiers in a video game—each level requires meeting specific milestones to level up toward full elimination.
The PTE framework evaluates countries on three key metrics for HCV patients:
- The proportion of those infected who get diagnosed.
- The share of diagnosed individuals who receive treatment.
- The distribution of clean needles and syringes to people who inject drugs—typically aiming for a certain number per person per year to prevent new transmissions.
Researchers, led by Zoe Ching, a Data Dashboard Intern at the Coalition for Global Hepatitis Elimination, examined data from 167 countries and territories. They drew from reliable sources like the WHO Global Health Observatory, Georgetown HIV Policy reports, United Nations population statistics, scientific studies, and profiles from the Coalition for Global Hepatitis Elimination. This comprehensive approach ensured a robust snapshot of where things stand.
The PTE tiers are structured as follows, with increasingly ambitious targets:
- Bronze: At least 60% of infected people diagnosed, 50% treated, and needle/syringe programs in place.
- Silver: 70% diagnosed, 60% treated, plus access to opioid agonist therapy alongside needle/syringe distribution.
- Gold: 80% diagnosed, 70% treated, and more than 150 needles/syringes provided per person who injects drugs annually.
Globally, we're looking at an estimated 50 million people living with HCV, with about 6,000 new cases popping up every single day. This rising tide of prevalence underscores why the WHO's 2030 targets are so crucial—they're designed to curb the disease's spread and save lives by ensuring better access to care.
The study's findings paint a mixed picture. Only 25 countries (15%) are on track to meet the 2030 mortality target, and just 24 (14%) for incidence. Among those hitting both goals—10 in total, or 6% of the analyzed areas—six are in the Americas: Bolivia, Brazil, Chile, Ecuador, Paraguay, and Peru. These nations show that with focused efforts, like widespread screening and affordable treatments, progress is possible.
Breaking it down by the PTE categories, needle/syringe coverage saw 66 countries (39%) achieving bronze, 53 (32%) silver, and 12 (7%) gold. For diagnosis, the numbers were lower: 20 (12%) bronze, 13 (8%) silver, and 10 (6%) gold. Treatment coverage followed a similar pattern: 29 (17%) bronze, 19 (11%) silver, and 10 (6%) gold. This variation highlights disparities, such as how no Southeast Asian countries reached even the basic bronze threshold, pointing to regional challenges like limited healthcare infrastructure or stigma around drug use.
Digging deeper into country-level insights, the analysis pinpoints where resources could make the biggest difference. For instance, the United States has reached 43% treatment coverage and bronze-level diagnosis at 68%, but still lags behind in fully scaling up. On the brighter side, Egypt and Norway have clinched gold for treatment, while Australia, Georgia, and Spain have secured silver. Yet, the overall trend suggests many nations are stuck in the middle, needing more investment to bridge the gaps.
In their conclusion, the researchers, including Choi and colleagues, emphasize that while these PTE tiers await official WHO validation, the provisional data identifies frontrunners and laggards. 'Challenges persist for the majority of countries,' they note. 'The US and others must dedicate resources to boost needle/syringe services, improve HCV treatment access, and implement policies for broader screening to speed up elimination.' And this is the part most people miss: Could stricter global policies on drug harm reduction or mandatory testing spark debate? Some argue for more aggressive interventions, like universal screening, while others worry about costs or privacy concerns.
For beginners wondering why this matters, picture this: Successful HCV elimination could prevent hundreds of thousands of deaths and reduce healthcare costs worldwide, freeing up resources for other health crises. But it's not just about numbers—it's about equity, ensuring that marginalized groups, like people who inject drugs, aren't left behind. Do you think governments are doing enough, or should we push for more international funding? Is the focus on prevention over treatment a smart move, or does it overlook those already infected? Share your thoughts in the comments—we'd love to hear differing opinions and spark a conversation.
By Alex Hillenbrand
References
- Zoe C, Lindsey H, John W, et al. Global Progress Toward Hepatitis C Elimination: Monitoring Achievements of WHO Goals and Targets for Hepatitis C Prevention and Care. Abstract presented at: American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025; November 7-11, Washington, DC.
- World Health Organization. Hepatitis C. World Health Organization. Published April 9, 2024. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (https://www.who.int/news-room/fact-sheets/detail/hepatitis-c)
For more hepatitis-related updates from The Liver Meeting 2025, click here (https://www.eatg.org/hiv-news/highlights-from-the-liver-meeting-2025/) .
